TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER
European Patent
19817052.4
Filed on 2021-06-10
19817052.4
Filed on 2021-06-10
TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER
Canada
3119736
Filed on 2021-05-12
3119736
Filed on 2021-05-12
IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
US Application 17/214,436
Filed on 2021-03-26
Filed on 2021-03-26
IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
Japan
2021-517344
Filed on 2021-03-26
2021-517344
Filed on 2021-03-26
COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD123 IMMUNOTHERAPY
Japan
2021-515623
Filed on 2021-03-19
2021-515623
Filed on 2021-03-19
TetraHydroxomate Chelators of Zirconium89 and Niobium90 for use in Diagnostic Applications
United Kingdom
14779019.0
Filed on 2014-03-12
14779019.0
Filed on 2014-03-12
TetraHydroxomate Chelators of Zirconium89 and Niobium90 for use in Diagnostic Applications
France
14779019.0
Filed on 2014-03-12
14779019.0
Filed on 2014-03-12
TetraHydroxomate Chelators of Zirconium89 and Niobium90 for use in Diagnostic Applications
Germany
14779019.0
Filed on 2014-03-12
14779019.0
Filed on 2014-03-12
Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer
Portugal
18188913.0
Filed on 2018-08-14
18188913.0
Filed on 2018-08-14
Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer
The Netherlands
18188913.0
Filed on 2018-08-14
18188913.0
Filed on 2018-08-14